Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of 2 PCCs on Apixaban PD in Healthy Subjects
NCT02074358Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2014
- Primary completion
- Apr 2014
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 1, randomised, open-label trial in anticoagulation therapy comparing Apixaban + Placebo, Apixaban + Cofact and Apixaban + Beriplex P/N (3 arms). Primary endpoint: Adjusted Mean Change in Endogenous Thrombin Potential (ETP). Started Feb 2014; status: completed.
02
Drugs
Human prothrombin complexbalfaxar
03
Conditions
anticoagulation therapy
Beyond the preview
Go deeper on NCT02074358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02074358.